semaglutide in oral form | Starts at $249/mo ACC 2025: Oral Semaglutide Reduces

Peptide Sciences semaglutide has caveats despite strong multi-lab purity evidence: two near-threshold purity misses and repeated underfill, including -28%

GLP-1 and dual GLP-1/GIP agonists may offer superior weight loss

In the health/care ecosystem, GLP-1 medications are now delivered omnichannel, via physician prescriptions from medical exam rooms for branded products heavily advertised on broadcast media.but also through direct-to-consumer channels such as Ro, Hims & Hers, and Noom, some channeling compounded GLP-1 products quite apart from the branded novel pharmaceuticals

With the recent announcement that the shortage of Ozempic and Wegovy is officially over, the FDA has declared that compounding pharmacies must stop producing and selling compounded semaglutide by May 22, 2025

Non-GMO, GMP Certified, and Third-Party Tested

$Hims & Hers Health (HIMS.US)$ With the FDA launching a green list initiative to block illegal or unverified GLP-1 drug ingredients from entering the U.S., companies like Hims & Hers Health (HIMS) may stand to benefit